Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

Sridhar, Sriram; Liu, Hao; Pham, Tuyet-Hang; Damera, Gautam; Newbold, Paul

doi:10.1186/s12931-018-0968-8

Respiratory Research

Table 2 Fold change from baseline in gene expression in patients with asthma and COPD

From: Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases

Genes	Asthma cohort		COPD cohort		Gene association with eosinophils/basophils
Genes	Benralizumab	Placebo	Benralizumab	Placebo	Gene association with eosinophils/basophils
CLC ^a	−4.68	−1.08	−5.32	−1.02	Eosinophil or basophil marker [46,47,48,49]
PRSS33 ^a	−2.45	1.04	−2.74	−1.1	Eosinophil or basophil marker [50]
OLIG2 ^a	−2.01	−1.05	−1.91	−1.01	Expressed in eosinophils and associated with the control of SIGLEC 8 expression [51]
FCER1A ^b	−1.96	−1.11	−1.84	−1.18	Fc epsilon receptor 1A, the high affinity receptor for IgE and expressed on eosinophils and basophils [52]
HRH4 ^b	−1.91	−1.03	−1.94	−1.17	Histamine receptor 4 expressed on eosinophils [53]
CCR3 ^b	−1.86	−1.14	−1.85	1.02	Chemokine receptor for eosinophils and basophils [54, 55]
IL5Rα ^a	−1.82	−1.06	−1.97	1.03	IL-5 receptor alpha expressed on eosinophils and basophils [56,57,58]
IDO1 ^b	−1.75	1.03	−1.83	−1.00	Eosinophil or basophil marker [59]
P2RY14 ^c	−1.71	−1.12	−1.70	−1.20	A purine receptor, P2Y14. Upregulated in eosinophils after allergen challenge and an asthma risk gene [60]
OLIG1 ^b	−1.70	1.04	−2.22	−1.28	Eosinophil marker [61]
ADORA3 ^a	−1.60	−1.02	−1.64	1.03	Adenosine A3 receptor expressed on eosinophils [62, 63]
CD9 ^b	−1.58	−1.21	−1.47	1.02	Motility and signal transduction expressed on eosinophils, basophils, and platelets [64]
ALOX15 ^b	−1.57	1	−1.64	−1.02	Gene for 15-lipoxygenase, an enzyme abundantly expressed in eosinophil [65]
CD24 ^b	−1.54	−1.06	−1.72	−1.11	Sialoglycoprotein expressed on mature granulocytes. Involved in IL-5 induced survival [66]

Data presented are fold change in gene expression
COPD chronic obstructive pulmonary disease, FDR false discovery rate
^aFold change in gene expression significant (FDR < 0.05) in both cohorts
^bFold change in gene expression significant by FDR in the asthma study and by p value in the COPD study
^cFold change in gene expression significant (FDR < 0.05) in the Phase IIb asthma study only

Back to article page

ISSN: 1465-993X

Contact us

General enquiries: journalsubmissions@springernature.com